**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 68154

**Manuscript Type:** ORIGINAL ARTICLE

***Case Control Study***

**Effect of Nephritis Rehabilitation Tablets combined with tacrolimus in treatment of idiopathic membranous nephropathy**

Lv W *et al*. Nephritis Rehabilitation Tablets for treatment of IMN

Wei Lv, Mei-Rong Wang, Cheng-Zhen Zhang, Xue-Xu Sun, Zhen-Zhen Yan, Xiao-Min Hu, Tao-Tao Wang

**Wei Lv, Cheng-Zhen Zhang, Xue-Xu Sun, Tao-Tao Wang,** Department of Nephology, China People’s Liberation Army 32298, Weifang 261000, Shandong Province, China

**Mei-Rong Wang,** Department of Pharmacy, China People’s Liberation Army 32298, Weifang 261000, Shandong Province, China

**Zhen-Zhen Yan, Xiao-Min Hu,** Department of Blood Purification, China People’s Liberation Army 32298, Weifang 261000, Shandong Province, China

**Author contributions:** Lv W, Wang MR, and Wang TT designed this study; Lv W, Wang MR, and Zhang CZ wrote this paper; Lv W, Wang MR, Zhang CZ, Sun XX, Yan ZZ, and Hu XM were responsible for sorting the data.

**Corresponding author: Tao-Tao Wang, BMed, Attending Doctor,** Department of Nephology, China People’s Liberation Army 32298, No. 256 North Palace West Street, Weicheng District, Weifang 261000, Shandong Province, China. 187254754@qq.com

**Received:** July 19, 2021

**Revised:** August 22, 2021

**Accepted:** October 14, 2021

**Published online:** December 6, 2021

**Abstract**

BACKGROUND

Idiopathic membranous nephropathy (IMN) has a high incidence in the middle-aged and elderly population, and poses a great threat to the physical and mental health and quality of life of patients. Nephritis Rehabilitation Tablets have many potential effects, such as clearing residual toxins, tumefying the kidney and spleen, replenishing qi, and nourishing yin, and have played an important role in the treatment of a variety of kidney diseases.

AIM

To investigate the efficacy and safety of Nephritis Rehabilitation Tablets combined with tacrolimus in the treatment of IMN.

METHODS

Eighty-four patients with IMN recruited from January 2017 to September 2020 were randomly divided into a study group (*n* = 42) and a control group (*n* = 42). On the basis of routine symptomatic treatment, both groups were treated with tacrolimus, and the study group was additionally treated with Nephritis Rehabilitation Tablets. Both groups were treated for 12 wk. The therapeutic effect, the levels of renal function indexes [serum creatinine (Scr), serum albumin, and 24-h urinary protein], urinary immunoglobulin (IgG4), membrane attack complex (C5b-9), and the incidence of adverse reactions were measured before and after 12 wk of treatment.

RESULTS

The total effective rate in the study group was significantly higher than that of the control group. Before treatment, there was no significant difference in Scr, serum albumin, or 24 h urinary protein between the two groups. After 12 wk of treatment, the levels of Scr and 24-h urinary protein in both groups were significantly lower and serum albumin was significantly higher than those before treatment (*P* < 0.05), and the levels of Scr and 24-h urinary protein were significantly lower (*P* = 0.003 and 0.000, respectively), and the level of serum albumin was significantly higher (*P* = 0.00) in the study group than in the control group. Before treatment, there was no significant difference in urinary IgG4 and C5b-9 levels between the study group and the control group (*P* = 0.336 and 0.438, respectively). After 12 wk of treatment, the levels of urinary IgG4 and C5b-9 in the two groups were lower than those before treatment, and the levels of urinary IgG4 and C5b-9 in the study group were significantly lower than those in the control group (*P* = 0.000). There was no significant difference in the incidence of adverse reactions between the two groups (*P* = 0.710).

CONCLUSION

Based on routine intervention, Nephritis Rehabilitation Tablets combined with tacrolimus in the treatment of IMN can effectively improve the renal function of patients and downregulate the expression of urinary IgG4 and C5b-9. In addition, they can improve the overall therapeutic effect while not increasing the risk of adverse reactions.

**Key Words:** Nephritis Rehabilitation Tablets; Tacrolimus; Idiopathic membranous nephropathy; Renal function; IgG4; C5b-9

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Lv W, Wang MR, Zhang CZ, Sun XX, Yan ZZ, Hu XM, Wang TT. Effect of Nephritis Rehabilitation Tablets combined with adjuvant tacrolimus in treatment of idiopathic membranous nephropathy. *World J Clin Cases* 2021; 9(34): 10464-10471

URL: https://www.wjgnet.com/2307-8960/full/v9/i34/10464.htm

DOI: https://dx.doi.org/10.12998/wjcc.v9.i34.10464

**Core Tip:** Generally, Nephritis Rehabilitation Tablets combined with tacrolimus in the treatment of idiopathic membranous nephropathy can effectively improve the renal function of patients and downregulate the expression of urinary IgG4 and C5b-9. In addition, they can help to improve the overall treatment effect while not increasing the risk of adverse reactions.

**INTRODUCTION**

Idiopathic membranous nephropathy (IMN) is a common pathological type of primary nephrotic syndrome. It has a high incidence in the middle-aged and elderly population, and poses a great threat to the physical and mental health and quality of life of patients[1,2]. The incidence of IMN has continued to increase in recent years, and safe and effective treatments are of significant research interest.

Glucocorticoid therapy alone has difficulty achieving ideal effects in IMN, and comprehensive intervention combined with immunosuppressants is usually needed[3]. Cyclophosphamide is commonly used in IMN and can achieve certain therapeutic effects, but the incidence of adverse reactions is high. Tacrolimus is a new calcineurin inhibitor that can effectively improve renal function with low dose and high safety. However, the overall therapeutic effect is still different from that expected in the clinic[4-6].

Attention has been given to the adjuvant therapeutic effects of traditional Chinese medicine Nephritis Rehabilitation Tablets in recent years. Nephritis Rehabilitation Tablets have many potential effects, such as clearing residual toxins, tumefying the kidney and spleen, replenishing qi, and nourishing yin, and have played an important role in the treatment of a variety of kidney diseases. In the present study, 84 patients with IMN at our hospital were selected and divided into groups to explore the therapeutic value of Nephritis Rehabilitation Tablets with tacrolimus.

**MATERIALS AND METHODS**

***General data***

Eighty-four patients with IMN were recruited from our hospital from January 2017 to September 2020 and were randomly divided into a study group (*n* = 42) and a control group (*n* = 42). In the study group, there were 27 males and 15 females, the age ranged from 46 to 77 years (mean, 61.56 ± 7.11 years), the course of disease ranged from 3.5 to 41.1 mo (mean, 22.29 ± 10.32 mo), and the disease stage was stage I (*n* = 23) or stage II (*n* = 19). In the control group, there were 29 males and 13 females, the age range was 45-79 years old with an average age of 62.01 ± 6.89 years, the course of disease range was 3.2-40.6 mo with an average of 21.91 ± 11.21 mo, and the disease stage was stage I (*n* = 24) or stage II (*n* = 18). The clinical data, including sex, age, course of disease, and stage of disease, were comparable between the two groups (*P* > 0.05).

***Selection criteria***

The inclusion criteria were: (1) The diagnosis of IMN was confirmed by renal puncture pathological examination, and the pathological stage was I or II; (2) age less than 80 years; (3) patients who were informed of the study and signed the consent form; (4) serum creatinine (Scr) < 133 umol/L; and (5) urinary protein ≥ 4 g/24 h.

The exclusion criteria were:(1) Patients with acquired immunodeficiency syndrome, hepatitis C, hepatitis B, *etc.*, who are unable to take immunosuppressant or hormone therapy; (2) patients with malignant tumor; (3) patients with severe infection; (4) patients with coagulation dysfunction; and (5) patients with allergic constitution or history of allergy to research drugs.

***Methods***

Both groups of patients were given routine symptomatic treatment after admission, including lipid reduction, anticoagulation, blood pressure reduction, diuresis and detumescence, and oral prednisone acetate tablets 0.5 mg/kg once a day (8 wk after treatment, the dose was reduced by 10% at an interval of 2 wk to a maintenance therapy of 10-15 mg/d). On this basis, different treatment schemes were adopted: The control group was treated with tacrolimus orally at 0.05-0.1 mg/kg/d twice a day, and blood trough concentration was maintained at 4-8 ng/L; the study group was treated with Nephritis Rehabilitation Tablets orally at 1.5 g three times a day in addition to the standard treatment of the control group. Both groups were treated for 12 wk.

***Evaluation of therapeutic effects***

After 12 wk of treatment, the therapeutic effects of the two groups were evaluate: Normalization of the levels of serum albumin and Scr and 24-h urinary protein < 0.3 g were considered as complete remission; 24-h urinary protein decreased by ≥ 50% or total < 1.0 g, normalization of serum albumin, and the increase or decrease of Scr ≤ 30% were considered as partial remission. The total effective rate was calculated as (complete remission + partial remission)/total cases × 100%[7]. The indexes of renal function (Scr, serum albumin, and 24-h urinary protein) were measured before treatment and after 12 wk of treatment. The levels of urinary immunoglobulin (IgG4) and membrane attack complex (C5b-9) in the two groups were measured before and after 12 wk of treatment. Mid-stream urine was taken and put into a clean container and stored at -20 ℃ for detection. The level of urinary C5b-9 was determined by enzyme-linked immunosorbent assay (ELISA), and the level of IgG4 was determined by double antibody sandwich ELISA. The incidence of adverse reactions in the two groups was measured.

***Statistical analysis***

The data were analyzed with SPSS 22.0. Continuous data are described as the mean ± SD and were compared by the *t*-test. Categorical data are described as frequency and constituent ratio (%) and were tested by the *χ*2 test. A nonparametric test was used to compare the continuous data that do not meet a normal distribution. *P* < 0.05 indicated that the difference was statistically significant.

**RESULTS**

***Therapeutic effects***

The total effective rate of the study group (90.48%) was significantly higher than that of the control group (71.43%, *P* = 0.026; Table 1).

***Renal function indexes***

Before treatment, there was no significant difference in Scr, serum albumin, or 24 h urinary protein between the study group and the control group (121.97 ± 40.36 µmol/L *vs* 124.55 ± 38.68 µmol/L, 24.21 ± 2.35 g/L *vs* 23.64 ± 2.51 g/L, 7.41 g ± 2.19 g *vs* 7.69 ± 2.32 g; *P* = 0.766, 0.286, and 0.571, respectively). After 12 wk of treatment, the quantitative levels of Scr and 24-h urinary protein in the two groups were significantly lower than those before treatment, and the level of serum albumin was significantly higher than that before treatment (*P* < 0.05). The levels of Scr and 24-h urinary protein in the study group (86.23 ± 21.61 µmol/L and 1.63 ± 0.59 g, respectively) were significantly lower than those in the control group (101.55 ± 23.67 g µmol/L and 2.89 ± 0.79 g; *P* = 0.003 and 0.000, respectively), and the level of serum albumin in the study group (36.69 ± 3.69 g/L) was significantly higher than that in the control group (31.26 ± 3.35 g/L, *P* = 0.00; Table 2).

***Urinary IgG4 and C5b-9 levels***

Before treatment, there was no significant difference in urinary IgG4 or C5b-9 level between the study group (14.67 ± 2.39 µg/mmol and 83.79 ± 10.66 ng/mg, respectively) and the control group (15.13 ± 2.53 µg/mmol, and 85.65 ± 11.20 ng/mg; *P* = 0.336 and 0.438, respectively). After 12 wk of treatment, the levels of urinary IgG4 and C5b-9 in the two groups were lower than those before treatment, and the levels of urinary IgG4 and C5b-9 in the study group (1.45 ± 0.29 µg/mmol and 44.81 ± 9.10 ng/mg, respectively) were significantly lower than those in the control group (3.13 ± 0.71 µg/mmol and 55.37 ± 10.23 ng/mg; *P* = 0.000 and 0.000, respectively; Table 3).

***Incidence of adverse reactions***

There was no significant difference in the incidence of adverse reactions between the study group (11.90%) and the control group (7.14%, *P* = 0.710; Table 4).

**DISCUSSION**

The incidence of IMN can account for more than 80% of nephrotic syndromes, and it can occur at any age. Most patients have different degrees of thrombosis and proteinuria, and 30% of patients' symptoms can be relieved by themselves. However, 50% of patients’ conditions progress rapidly and can progress to end-stage kidney disease within 10 years, which is a great threat[8,9]. As a consequence, targeted treatment should be given quickly after the onset of IMN.

Glucocorticoids are an important therapeutic drug for IMN. However, hormone therapy alone has difficulty achieving ideal results. Relevant statistics show that the incidence of renal insufficiency in IMN patients without immunosuppressant can reach 40%. The combination of hormone and immunosuppressant therapy can effectively relieve clinical symptoms, improve renal survival, and inhibit the progression of renal insufficiency[10,11]. Cyclophosphamide is the most commonly used immunosuppressant in the clinic and can block the synthesis of DNA in cells to achieve immunosuppression. Combined with hormones, it can enhance hormone sensitivity and improve drug efficacy. However, the incidence of adverse events such as gonadal inhibition, liver function injury, and myelosuppression is high, resulting in significant limitations in its clinical application[12]. Tacrolimus is a new type of immunosuppressant that can interfere with calcium-dependent signal transduction, increase calcium influx, prevent dephosphorylation of activated T nuclear factors and transcription of inflammatory factors, and inhibit T cell proliferation. Lymphocyte aggregation is prevented in the early stage of the immune reaction and thus plays a therapeutic role[13,14]. In addition, the value of adjuvant therapy with traditional Chinese medicine in IMN has received widespread attention in recent years. There is no record of the name of IMN in traditional Chinese medicine, but according to its characteristics, it is classified into the categories of "edema" and "turbid urine". It is considered that the pathological mechanism of the disease lies in the deficiency of the spleen and kidney, blood stasis, damp-heat, wind evil, and water dampness. Spleen deficiency can lead to deficiency of qi and blood, and retention of damp turbidity leads to edema. Kidney deficiency can cause nontransformation of qi and water, such as edema and kidney loss and storage, to form proteinuria[15]. Combined with the above etiology and pathogenesis, on the basis of routine intervention such as tacrolimus, Nephritis Rehabilitation Tablets were used to treat patients with IMN at our hospital. The results showed that the total effective rate of the study group was higher than that of the control group, the quantitative levels of Scr and 24-h urinary protein of the study group were lower than those of the control group, and the level of serum albumin was higher than that of the control group. This showed that the combination of tacrolimus and Nephritis Rehabilitation Tablets has more significant advantages in improving the renal function of patients with IMN, which is helpful for improving the overall therapeutic effect on the disease. The main reason is that the main components of Nephritis Rehabilitation Tablets include *Salvia miltiorrhiza*, *Ginseng*, *Hedyotis diffuse*, *Motherwort*, and Eu*commia ulmoides*, which have many effects, such as dispelling dampness and removing blood stasis, diuresis, and detumescence; tonifying qi and nourishing yin; and tonifying the kidney and detoxification. In addition, *Motherwort*, *Salvia miltiorrhiza*, and *Hedyotis diffusa* have many effects, such as anti-erythrocyte and anti-platelet aggregation, which can reduce blood viscosity, increase renal blood flow, and prevent thrombosis[16,17]. In addition, Nephritis Rehabilitation Tablets can reduce capillary permeability, regulate microcirculation and lipid metabolism, reduce swelling and diuresis, relieve urinary protein, enhance immunity, and improve renal function. In addition, some studies have demonstrated that Nephritis Rehabilitation Tablets can repair glomerular podocytes and reduce the expression of transforming growth factor beta 1 and α-smooth muscle actin in the renal interstitium. In addition, it can maintain the filtration barrier, improve the precipitation of extracellular matrix components such as laminin and fibronectin, and regulate immune function and renal function. Moreover, it can increase liver albumin synthesis, increase plasma protein levels, and antagonize glucocorticoid-induced adverse reactions[18].

In addition, urinary IgG4 can reflect renal IgG4 deposition and is closely related to IMN disease activity. Moreover, studies have shown that IMN autoantibodies play an intermediary role, while complement proteins play an important role in organ-specific autoimmune diseases. Podocyte antigens can bind to antibodies to form subepithelial *in situ* immune complexes, and complement activation can produce C5b-9. As a consequence, the condition, therapeutic effect, and prognosis of IMN can be evaluated by monitoring the levels of urinary IgG4 and C5b-9[19,20]. The levels of urinary IgG4 and C5b-9 in the study group were lower than those in the control group (*P* < 0.05), which further confirmed that Nephritis Rehabilitation Tablets combined with tacrolimus had high therapeutic value in IMN, which could reduce the contents of urinary IgG4 and C5b-9 and improve the therapeutic effect of the disease. In addition, from the results of this study, it can be concluded that there was no significant difference in the incidence of adverse reactions between the two groups, indicating that the combination of Nephritis Rehabilitation Tablets and tacrolimus can not only achieve a good therapeutic effect but also have a satisfactory safety profile.

**CONCLUSION**

Generally, Nephritis Rehabilitation Tablets combined with tacrolimus in the treatment of IMN can effectively improve the renal function of patients and downregulate the expression of urinary IgG4 and C5b-9 on the basis of routine intervention. In addition, they can help to improve the overall treatment effect while not increasing the risk of adverse reactions. However, since this study had fewer samples, further multi-center research is required to confirm our findings.

**ARTICLE HIGHLIGHTS**

***Research background***

Idiopathic membranous nephropathy (IMN) has a high incidence in the middle-aged and elderly population, and poses a great threat to the physical and mental health and quality of life of patients. The incidence of IMN has continued to increase in recent years, and safe and effective treatments are of significant research interest.

***Research motivation***

Glucocorticoid therapy alone has difficulty achieving ideal effects in IMN, and the incidence of adverse reactions is high. Tacrolimus is a new calcineurin inhibitor that can effectively improve renal function with low dose and high safety.

***Research objectives***

This study aimed to investigate the efficacy and safety of Nephritis Rehabilitation Tablets combined with tacrolimus in the treatment of IMN.

***Research methods***

On the basis of routine symptomatic treatment, the control group was treated with tacrolimus, and the study group was treated with nephritis rehabilitation tablets in addition to control group treatment. Both groups were treated for 12 wk. The therapeutic effect, the levels of renal function indexes, and the incidence of adverse reactions were measured before and after 12 wk of treatment.

***Research results***

The results showed that the total effective rate of the study group was higher than that of the control group, the quantitative levels of Scr and 24-h urinary protein of the study group were lower than those of the control group, and the level of serum albumin was higher than that of the control group. IMN autoantibodies play an intermediary role, while complement proteins play an important role in organ-specific autoimmune diseases. The levels of urinary IgG4 and C5b-9 in the study group were lower than those in the control group.

***Research conclusions***

Nephritis Rehabilitation Tablets combined with tacrolimus in the treatment of IMN can effectively improve the renal function of patients and downregulate the expression of urinary IgG4 and C5b-9. In addition, they can improve the overall therapeutic effect while not increasing the risk of adverse reactions.

***Research perspectives***

This study has fewer samples, and further multi-center research is required to confirm our findings.

**REFERENCES**

1 **Cui W**, Lu X, Min X, Liu M, Guan S, Wang Y, Luo M, Li W, Li Q, Dong W, Miao L, Luo P. Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy. *Braz J Med Biol Res* 2017; **50**: e5976 [PMID: 28355356 DOI: 10.1590/1414-431X20175976]

2 **Liang Q**, Li H, Xie X, Qu F, Li X, Chen J. The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy. *Ren Fail* 2017; **39**: 512-518 [PMID: 28562168 DOI: 10.1080/0886022X.2017.1325371]

3 **Zou H**, Jiang F, Xu G. Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy. *Ren Fail* 2019; **41**: 673-681 [PMID: 31354007 DOI: 10.1080/0886022X.2019.1637758]

4 **van den Brand JAJG**, Ruggenenti P, Chianca A, Hofstra JM, Perna A, Ruggiero B, Wetzels JFM, Remuzzi G. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. *J Am Soc Nephrol* 2017; **28**: 2729-2737 [PMID: 28487395 DOI: 10.1681/ASN.2016091022]

5 **Qin HZ**, Liu L, Liang SS, Shi JS, Zheng CX, Hou Q, Lu YH, Le WB. Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients. *BMC Nephrol* 2017; **18**: 2 [PMID: 28056860 DOI: 10.1186/s12882-016-0427-z]

6 **Lu W**, Gong S, Li J, Luo H, Wang Y. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis. *Medicine (Baltimore)* 2020; **99**: e19804 [PMID: 32311997 DOI: 10.1097/MD.0000000000019804]

7 **Zhu LB**, Liu LL, Yao L, Wang LN. Efficacy and Safety of Tacrolimus Versus Cyclophosphamide for Primary Membranous Nephropathy: A Meta-Analysis. *Drugs* 2017; **77**: 187-199 [PMID: 28084563 DOI: 10.1007/s40265-016-0683-z]

8 **Goździk M**, Płuciennik A, Zawiasa-Bryszewska A, Nowicka M, Nowicka Z, Wągrowska-Danilewicz M, Kurnatowska I. Acute Kidney Injury Following Exposure to Calcineurin Inhibitors in a Patient with Idiopathic Membranous Nephropathy. *Drug Saf Case Rep* 2019; **6**: 9 [PMID: 31587119 DOI: 10.1007/s40800-019-0103-x]

9 **Shao L**, Jin J, Ye B, Xu B, Li Y, Gong J, Zhang J, Chen M, He Q. New-Onset Diabetes Mellitus in Patients with Idiopathic Membranous Nephropathy Undergoing Tacrolimus and Low-Dose Corticosteroid Therapy. *Kidney Blood Press Res* 2019; **44**: 1352-1362 [PMID: 31645044 DOI: 10.1159/000502693]

10 **Zotta F**, Di Stasio E, Manzione A, Pirozzi N, Stoppacciaro A, Menè P. [Steroid and cyclosporine therapy in idiopathic membranous nephropathy: monocentric experience and literature review]. *G Ital Nefrol* 2019; **36** [PMID: 31251003]

11 **Liu D**, Yang Y, Kuang F, Qing S, Hu B, Yu X. Risk of infection with different immunosuppressive drugs combined with glucocorticoids for the treatment of idiopathic membranous nephropathy: A pairwise and network meta-analysis. *Int Immunopharmacol* 2019; **70**: 354-361 [PMID: 30852290 DOI: 10.1016/j.intimp.2019.03.002]

12 **Zou H**, Jiang F, Xu G. Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy. *Intern Med J* 2020; **50**: 612-619 [PMID: 31389094 DOI: 10.1111/imj.14446]

13 **Araya AA,** Tasnif Y. Tacrolimus. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing, 2021 [PMID: 31335038]

14 **Zhu Y**, Zhang M, Wang F, Lu J, Chen R, Xie Q, Sun J, Xue J, Hao C, Lin S. The calcineurin regulatory subunit polymorphism and the treatment efficacy of tacrolimus for idiopathic membranous nephropathy. *Int Immunopharmacol* 2018; **65**: 422-428 [PMID: 30388516 DOI: 10.1016/j.intimp.2018.10.038]

15 **Zhang Z**, Lu X, Dong L, Ma J, Fan X. Clinical observation on the effect of Wuzhi soft capsule on FK506 concentration in membranous nephropathy patients. *Medicine (Baltimore)* 2019; **98**: e18150 [PMID: 31770256 DOI: 10.1097/MD.0000000000018150]

16 **Jiang C**, Zhu W, Shao Q, Yan X, Jin B, Zhang M, Xu B. Tanshinone IIA Protects Against Folic Acid-Induced Acute Kidney Injury. *Am J Chin Med* 2016; **44**: 737-753 [PMID: 27222061 DOI: 10.1142/S0192415X16500403]

17 **Karunasagara S**, Hong GL, Park SR, Lee NH, Jung DY, Kim TW, Jung JY. Korean red ginseng attenuates hyperglycemia-induced renal inflammation and fibrosis *via* accelerated autophagy and protects against diabetic kidney disease. *J Ethnopharmacol* 2020; **254**: 112693 [PMID: 32112899 DOI: 10.1016/j.jep.2020.112693]

18 **Wang L**, Wang YH, Zhang XH, Yang XL, Wei HL, An ZC, Yu BR, Du DQ, Guo Y, Liu HF. Effectiveness comparisons of traditional Chinese medicine on treating diabetic nephropathy proteinuria: A systematic review and meta-analysis. *Medicine (Baltimore)* 2019; **98**: e17495 [PMID: 31651852 DOI: 10.1097/MD.0000000000017495]

19 **Hou J**, Cheng Y, Hou Y, Wu H. Lower Serum and Higher Urine Immunoglobulin G Are Associated with an Increased Severity of Idiopathic Membranous Nephropathy. *Ann Clin Lab Sci* 2019; **49**: 777-784 [PMID: 31882429]

20 **Liu W**, Gao C, Liu Z, Dai H, Feng Z, Dong Z, Zheng Y, Gao Y, Tian X, Liu B. Idiopathic Membranous Nephropathy: Glomerular Pathological Pattern Caused by Extrarenal Immunity Activity. *Front Immunol* 2020; **11**: 1846 [PMID: 33042109 DOI: 10.3389/fimmu.2020.01846]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the Hospital of No. 80 Group Army Institutional Review Board (Approval No. 63).

**Informed consent statement:** All patients gave informed consent.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest to disclose.

**Data sharing statement:** No additional data are available.

**STROBE Statement:** The manuscript was checked and revised according to the STROBE Statement.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:**Unsolicited article; Externally peer reviewed.

**Peer-review started:** July 19, 2021

**First decision:** August 19, 2021

**Article in press:** October 14, 2021

**Specialty type:** Urology and Nephrology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Rizzi M **S-Editor:** Wang JL **L-Editor:** Wang TQ **P-Editor:** Wang JL

**Table 1 Comparison of therapeutic effects between the two groups, *n* (%)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Group** | **Number** | **Complete remission** | **Partial remission** | **Invalid** | **Total efficiency** |
| Study | 42 | 26 (61.90) | 12 (28.57) | 4 (9.52) | 38 (90.48) |
| Control | 42 | 16 (38.10) | 14 (33.33) | 12 (28.57) | 30 (71.43) |
| *χ*2 |  |  |  |  | 4.941 |
| *P* value |  |  |  |  | 0.026 |

**Table 2 Comparison of renal function indexes between the two groups (mean ± SD)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Time** | **Group** | **Number** | **Scr (umol/L)** | **Serum albumin (g/L)** | **24 h urinary protein quantification (g)** |
| Before treatment | Study | 42 | 121.97 ± 40.36 | 24.21 ± 2.35 | 7.41 ± 2.19 |
| Control | 42 | 124.55 ± 38.68 | 23.64 ± 2.51 | 7.69 ± 2.32 |
| *t* |  | 0.299 | 1.074 | 0.569 |
| *P* value |  | 0.766 | 0.286 | 0.571 |
| After 12 weeks of treatment | Study | 42 | 86.23 ± 21.61a | 36.69 ± 3.71a | 1.63 ± 0.59a |
| Control | 42 | 101.55 ± 23.67a | 31.26 ± 3.35a | 2.89 ± 0.79a |
| *t* |  | 3.098 | 7.040 | 8.282 |
| *P* value |  | 0.003 | 0.000 | 0.000 |

a*P <* 0.05, before treatment *vs* after 12 wk of treatment.

**Table 3 Comparison of urinary IgG4 and C5b-9 levels between the two groups (mean ± SD)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Time** | **Group** | **Number** | **IgG4 (ug/mmol)** | **C5b-9 (ng/mg)** |
| Before treatment | Study | 42 | 14.67 ± 2.39 | 83.79 ± 10.66 |
| Control | 42 | 15.19 ± 2.53 | 85.65 ± 11.20 |
| *t* |  | 0.968 | 0.780 |
| *P* value |  | 0.336 | 0.438 |
| After 12 weeks of treatment | Study | 42 | 1.45 ± 0.29a | 44.81 ± 9.39a |
| Control | 42 | 3.13 ± 0.71a | 55.37 ± 10.23a |
| *t* |  | 14.196 | 4.928 |
| *P* value |  | 0.000 | 0.000 |

a*P <* 0.05, before treatment *vs* after 12 wk of treatment.

**Table 4 Comparison of incidence of adverse reactions between the two groups, *n* (%)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Group** | **Number** | **Elevated transaminase** | **Gastrointestinal reaction** | **Vomiting and nausea** | **Dizzy** | **Total incidence rate** |
| Study | 42 | 1 (2.38) | 1 (2.38) | 2 (4.76) | 1 (2.38) | 5 (11.90) |
| Control | 42 | 1 (2.38) | 1 (2.38) | 0 (0.00) | 1 (2.38) | 3 (7.14) |
| *χ2* |  |  |  |  |  | 0.138 |
| *P* value |  |  |  |  |  | 0.710 |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**